lilly 1 post

• The Next Wave of Obesity Drugs: Opportunities and Risks for Investors 🌊
  26 January 2025  ·  amycretin CagriSema Eli Lilly
  GLP-1 weight loss drugs Wegovy® (semaglutide) and Zepbound® (tirzepatide) from Novo Nordisk and Eli Lilly hit markets like a tsunami, when they were approved in June 2021 and November 2023 , due to their unprecedented weight-loss efficacy 🌊 The next waves might not be as colossal, but they still hol